Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GHB-003
- Development stage
- Preclinical
- Lead developer
- Gatehouse Bio
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
GHB-003 is a preclinical therapeutic candidate being developed by Gatehouse Bio for the treatment of Alzheimer's disease. The asset was identified using the company's proprietary AI-driven platform, which focuses on small non-coding RNAs (sncRNAs) as both biomarkers and therapeutic targets. Gatehouse Bio's approach involves identifying disease-driving sRNA signatures and developing sRNA-based or sRNA-targeting therapeutics to modulate these pathways. As of early 2024, GHB-003 remains in the preclinical stage, and specific details regarding its molecular target or precise mechanism of action within the Alzheimer's pathology have not been publicly disclosed.
Beyond the preview
Go deeper on GHB-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GHB-003.